Literature DB >> 25387153

Phosphatidylinositol 3-Kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring.

Martin Andrs1, Jan Korabecny, Daniel Jun, Zdenek Hodny, Jiri Bartek, Kamil Kuca.   

Abstract

Phosphatidylinositol 3-kinases (PI3Ks) and phosphatidylinositol 3-kinase-related protein kinases (PIKKs) are two related families of kinases that play key roles in regulation of cell proliferation, metabolism, migration, survival, and responses to diverse stresses including DNA damage. To design novel efficient strategies for treatment of cancer and other diseases, these kinases have been extensively studied. Despite their different nature, these two kinase families have related origin and share very similar kinase domains. Therefore, chemical inhibitors of these kinases usually carry analogous structural motifs. The most common feature of these inhibitors is a critical hydrogen bond to morpholine oxygen, initially present in the early nonspecific PI3K and PIKK inhibitor 3 (LY294002), which served as a valuable chemical tool for development of many additional PI3K and PIKK inhibitors. While several PI3K pathway inhibitors have recently shown promising clinical responses, inhibitors of the DNA damage-related PIKKs remain thus far largely in preclinical development.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25387153     DOI: 10.1021/jm501026z

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  17 in total

1.  Discovery of an Atropisomeric PI3Kβ Selective Inhibitor through Optimization of the Hinge Binding Motif.

Authors:  Stephane Perreault; Fatima Arjmand; Jayaraman Chandrasekhar; Jia Hao; Kathleen S Keegan; David Koditek; Eve-Irene Lepist; Clinton K Matson; Mary E McGrath; Leena Patel; Kassandra Sedillo; Joseph Therrien; Nicholas A Till; Adrian Tomkinson; Jennifer Treiberg; Yelena Zherebina; Gary Phillips
Journal:  ACS Med Chem Lett       Date:  2020-04-13       Impact factor: 4.345

2.  Apoptotic effects of high-dose rapamycin occur in S-phase of the cell cycle.

Authors:  Mahesh Saqcena; Deven Patel; Deepak Menon; Suman Mukhopadhyay; David A Foster
Journal:  Cell Cycle       Date:  2015-05-06       Impact factor: 4.534

3.  Discovery of Novel and Orally Bioavailable Inhibitors of PI3 Kinase Based on Indazole Substituted Morpholino-Triazines.

Authors:  Sundeep Dugar; Frank P Hollinger; Dinesh Mahajan; Somdutta Sen; Bilash Kuila; Reena Arora; Yogesh Pawar; Vaibhav Shinde; Mahesh Rahinj; Kamal K Kapoor; Rahul Bhumkar; Santosh Rai; Rakesh Kulkarni
Journal:  ACS Med Chem Lett       Date:  2015-11-02       Impact factor: 4.345

Review 4.  DNA repair targeted therapy: The past or future of cancer treatment?

Authors:  Navnath S Gavande; Pamela S VanderVere-Carozza; Hilary D Hinshaw; Shadia I Jalal; Catherine R Sears; Katherine S Pawelczak; John J Turchi
Journal:  Pharmacol Ther       Date:  2016-02-16       Impact factor: 12.310

5.  Identification and Utilization of a Chemical Probe to Interrogate the Roles of PIKfyve in the Lifecycle of β-Coronaviruses.

Authors:  David H Drewry; Frances M Potjewyd; Armin Bayati; Jeffery L Smith; Rebekah J Dickmander; Stefanie Howell; Sharon Taft-Benz; Sophia M Min; Mohammad Anwar Hossain; Mark Heise; Peter S McPherson; Nathaniel J Moorman; Alison D Axtman
Journal:  J Med Chem       Date:  2022-09-16       Impact factor: 8.039

Review 6.  Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment.

Authors:  Xianbo Wu; Yihua Xu; Qi Liang; Xinwei Yang; Jianli Huang; Jie Wang; Hong Zhang; Jianyou Shi
Journal:  Front Pharmacol       Date:  2022-05-09       Impact factor: 5.988

7.  Discovery of an Orally Bioavailable Dual PI3K/mTOR Inhibitor Based on Sulfonyl-Substituted Morpholinopyrimidines.

Authors:  Sida Shen; Xiangyu He; Zheng Yang; Liang Zhang; Yingtao Liu; Zhiyuan Zhang; Weiwei Wang; Wei Liu; Yufeng Li; Dong Huang; Kai Sun; Xiaojing Ni; Xu Yang; Xinxin Chu; Yumin Cui; Qiang Lv; Jiong Lan; Fusheng Zhou
Journal:  ACS Med Chem Lett       Date:  2018-06-25       Impact factor: 4.345

8.  CZ415, a Highly Selective mTOR Inhibitor Showing in Vivo Efficacy in a Collagen Induced Arthritis Model.

Authors:  Andrew D Cansfield; Tammy Ladduwahetty; Mihiro Sunose; Katie Ellard; Rosemary Lynch; Anthea L Newton; Ann Lewis; Gavin Bennett; Nico Zinn; Douglas W Thomson; Anne J Rüger; John T Feutrill; Oliver Rausch; Alan P Watt; Giovanna Bergamini
Journal:  ACS Med Chem Lett       Date:  2016-06-10       Impact factor: 4.345

9.  Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946).

Authors:  William J Scott; Martin F Hentemann; R Bruce Rowley; Cathy O Bull; Susan Jenkins; Ann M Bullion; Jeffrey Johnson; Anikó Redman; Arthur H Robbins; William Esler; R Paul Fracasso; Timothy Garrison; Mark Hamilton; Martin Michels; Jill E Wood; Dean P Wilkie; Hong Xiao; Joan Levy; Enrico Stasik; Ningshu Liu; Martina Schaefer; Michael Brands; Julien Lefranc
Journal:  ChemMedChem       Date:  2016-06-16       Impact factor: 3.466

10.  Objective, Quantitative, Data-Driven Assessment of Chemical Probes.

Authors:  Albert A Antolin; Joseph E Tym; Angeliki Komianou; Ian Collins; Paul Workman; Bissan Al-Lazikani
Journal:  Cell Chem Biol       Date:  2017-12-14       Impact factor: 8.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.